346 related articles for article (PubMed ID: 30227305)
21.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
22. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract][Full Text] [Related]
23. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
24. Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Johansson P; Klein-Hitpass L; Grabellus F; Arnold G; Klapper W; Pförtner R; Dührsen U; Eckstein A; Dürig J; Küppers R
Oncotarget; 2016 Sep; 7(38):62627-62639. PubMed ID: 27566587
[TBL] [Abstract][Full Text] [Related]
25. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.
Bödör C; Alpár D; Marosvári D; Galik B; Rajnai H; Bátai B; Nagy Á; Kajtár B; Burján A; Deák B; Schneider T; Alizadeh H; Matolcsy A; Brandner S; Storhoff J; Chen N; Liu M; Ghali N; Csala I; Bagó AG; Gyenesei A; Reiniger L
J Neuropathol Exp Neurol; 2020 Feb; 79(2):176-183. PubMed ID: 31886867
[TBL] [Abstract][Full Text] [Related]
26. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
27. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
28. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.
Roth P; Keller A; Hoheisel JD; Codo P; Bauer AS; Backes C; Leidinger P; Meese E; Thiel E; Korfel A; Weller M
Eur J Cancer; 2015 Feb; 51(3):382-90. PubMed ID: 25534293
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
[TBL] [Abstract][Full Text] [Related]
30. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
31. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
[TBL] [Abstract][Full Text] [Related]
32. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
33. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic correlates of
Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
36. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
[TBL] [Abstract][Full Text] [Related]
37. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
[No Abstract] [Full Text] [Related]
38. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
39. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
